APO Research
Talk to an analyst

APO RESEARCH · REPORT

Oral Factor Xa Inhibitors

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Oral Factor Xa Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

28 December 2025191 pages

Choose your research edition.

Industry ResearchOral Factor Xa Inhibitors Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Oral Factor Xa Inhibitors Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Oral Factor Xa Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oral Factor Xa Inhibitors Market Outlook and Growth Opportunities 2026203 pages · $4,250 USDMarket Analysis & ForecastGlobal Oral Factor Xa Inhibitors Market Analysis and Forecast 2026-2032200 pages · $4,950 USD

Market perspective

The global Oral Factor Xa Inhibitors market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Oral Factor Xa Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Oral Factor Xa Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Oral Factor Xa Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Oral Factor Xa Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Oral Factor Xa Inhibitors include Accord Healthcare, Apotex, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Janssen Pharmaceuticals, Lupin, Mylan and Pfizer, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Oral Factor Xa Inhibitors market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Oral Factor Xa Inhibitors and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Oral Factor Xa Inhibitors sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Oral Factor Xa Inhibitors market size, projected growth trends, production technologies, key applications, and end-use industries.

Oral Factor Xa Inhibitors Segment by Company

Accord Healthcare

Apotex

Bayer

Bristol Myers Squibb

Daiichi Sankyo

Janssen Pharmaceuticals

Lupin

Mylan

Pfizer

Zydus

HEC Pharma

Hansoh Pharma

Huahai Pharmaceutical

Shanghai Huilun Pharmaceutical

Qilu Pharmaceutical

Cspc Ouyi Pharmaceutical

Yangtze River Pharmaceutical

Zhejiang Hisun Pharmaceutical

Chia Tai Tianqing Pharmaceutical

Oral Factor Xa Inhibitors Segment by Type

Edoxaban

Rivaroxaban

Apixaban

Oral Factor Xa Inhibitors Segment by Application

Pulmonary Embolism

Deep Vein Thrombosis

Atrial Fibrillation

Other

Oral Factor Xa Inhibitors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oral Factor Xa Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oral Factor Xa Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oral Factor Xa Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Oral Factor Xa Inhibitors market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Oral Factor Xa Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Oral Factor Xa Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Oral Factor Xa Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Oral Factor Xa Inhibitors Industry Trends Table 2. Oral Factor Xa Inhibitors Industry Drivers Table 3. Oral Factor Xa Inhibitors Industry Opportunities and Challenges Table 4. Oral Factor Xa Inhibitors Industry Restraints Table 5. Global Oral Factor Xa Inhibitors Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Oral Factor Xa Inhibitors Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Oral Factor Xa Inhibitors Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Oral Factor Xa Inhibitors Sales Market Share by Manufacturers Table 9. Global Oral Factor Xa Inhibitors Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Oral Factor Xa Inhibitors Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Oral Factor Xa Inhibitors Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Oral Factor Xa Inhibitors Manufacturers, Product Type & Application Table 13. Global Oral Factor Xa Inhibitors Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Oral Factor Xa Inhibitors by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Edoxaban Table 17. Major Manufacturers of Rivaroxaban Table 18. Major Manufacturers of Apixaban Table 19. Global Oral Factor Xa Inhibitors Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Oral Factor Xa Inhibitors Sales by Type (2021-2026) & (K Units) Table 21. Global Oral Factor Xa Inhibitors Sales by Type (2027-2032) & (K Units) Table 22. Global Oral Factor Xa Inhibitors Sales Market Share by Type (2021-2026) Table 23. Global Oral Factor Xa Inhibitors Sales Market Share by Type (2027-2032) Table 24. Global Oral Factor Xa Inhibitors Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 25. Global Oral Factor Xa Inhibitors Revenue by Type (2021-2026) & (K Units) Table 26. Global Oral Factor Xa Inhibitors Revenue by Type (2027-2032) & (K Units) Table 27. Global Oral Factor Xa Inhibitors Revenue Market Share by Type (2021-2026) Table 28. Global Oral Factor Xa Inhibitors Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Pulmonary Embolism Table 30. Major Manufacturers of Deep Vein Thrombosis Table 31. Major Manufacturers of Atrial Fibrillation Table 32. Major Manufacturers of Other Table 33. Global Oral Factor Xa Inhibitors Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Oral Factor Xa Inhibitors Sales by Application (2021-2026) & (K Units) Table 35. Global Oral Factor Xa Inhibitors Sales by Application (2027-2032) & (K Units) Table 36. Global Oral Factor Xa Inhibitors Sales Market Share by Application (2021-2026) Table 37. Global Oral Factor Xa Inhibitors Sales Market Share by Application (2027-2032) Table 38. Global Oral Factor Xa Inhibitors Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 39. Global Oral Factor Xa Inhibitors Revenue by Application (2021-2026) & (K Units) Table 40. Global Oral Factor Xa Inhibitors Revenue by Application (2027-2032) & (K Units) Table 41. Global Oral Factor Xa Inhibitors Revenue Market Share by Application (2021-2026) Table 42. Global Oral Factor Xa Inhibitors Revenue Market Share by Application (2027-2032) Table 43. Global Oral Factor Xa Inhibitors Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Oral Factor Xa Inhibitors Sales by Region (2021-2026) & (K Units) Table 45. Global Oral Factor Xa Inhibitors Sales Market Share by Region (2021-2026) Table 46. Global Oral Factor Xa Inhibitors Sales Forecasted by Region (2027-2032) & (K Units) Table 47. Global Oral Factor Xa Inhibitors Sales Forecasted Market Share by Region (2027-2032) Table 48. North America Oral Factor Xa Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 49. North America Oral Factor Xa Inhibitors Sales by Country (2021-2026) & (K Units) Table 50. North America Oral Factor Xa Inhibitors Sales by Country (2027-2032) & (K Units) Table 51. Europe Oral Factor Xa Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. Europe Oral Factor Xa Inhibitors Sales by Country (2021-2026) & (K Units) Table 53. Europe Oral Factor Xa Inhibitors Sales by Country (2027-2032) & (K Units) Table 54. Asia Pacific Oral Factor Xa Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Asia Pacific Oral Factor Xa Inhibitors Sales by Country (2021-2026) & (K Units) Table 56. Asia Pacific Oral Factor Xa Inhibitors Sales by Country (2027-2032) & (K Units) Table 57. South America, Middle East and Africa Oral Factor Xa Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. South America, Middle East and Africa Oral Factor Xa Inhibitors Sales by Country (2021-2026) & (K Units) Table 59. South America, Middle East and Africa Oral Factor Xa Inhibitors Sales by Country (2027-2032) & (K Units) Table 60. Global Oral Factor Xa Inhibitors Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Oral Factor Xa Inhibitors Revenue by Region (2021-2026) & (US$ Million) Table 62. Global Oral Factor Xa Inhibitors Revenue by Region (2027-2032) & (US$ Million) Table 63. Global Oral Factor Xa Inhibitors Revenue Market Share by Region (2021-2026) Table 64. Global Oral Factor Xa Inhibitors Revenue Market Share by Region (2027-2032) Table 65. Accord Healthcare Company Information Table 66. Accord Healthcare Business Overview Table 67. Accord Healthcare Oral Factor Xa Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Accord Healthcare Oral Factor Xa Inhibitors Product Portfolio Table 69. Accord Healthcare Recent Development Table 70. Apotex Company Information Table 71. Apotex Business Overview Table 72. Apotex Oral Factor Xa Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Apotex Oral Factor Xa Inhibitors Product Portfolio Table 74. Apotex Recent Development Table 75. Bayer Company Information Table 76. Bayer Business Overview Table 77. Bayer Oral Factor Xa Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Bayer Oral Factor Xa Inhibitors Product Portfolio Table 79. Bayer Recent Development Table 80. Bristol Myers Squibb Company Information Table 81. Bristol Myers Squibb Business Overview Table 82. Bristol Myers Squibb Oral Factor Xa Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Bristol Myers Squibb Oral Factor Xa Inhibitors Product Portfolio Table 84. Bristol Myers Squibb Recent Development Table 85. Daiichi Sankyo Company Information Table 86. Daiichi Sankyo Business Overview Table 87. Daiichi Sankyo Oral Factor Xa Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Daiichi Sankyo Oral Factor Xa Inhibitors Product Portfolio Table 89. Daiichi Sankyo Recent Development Table 90. Janssen Pharmaceuticals Company Information Table 91. Janssen Pharmaceuticals Business Overview Table 92. Janssen Pharmaceuticals Oral Factor Xa Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Janssen Pharmaceuticals Oral Factor Xa Inhibitors Product Portfolio Table 94. Janssen Pharmaceuticals Recent Development Table 95. Lupin Company Information Table 96. Lupin Business Overview Table 97. Lupin Oral Factor Xa Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. Lupin Oral Factor Xa Inhibitors Product Portfolio Table 99. Lupin Recent Development Table 100. Mylan Company Information Table 101. Mylan Business Overview Table 102. Mylan Oral Factor Xa Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. Mylan Oral Factor Xa Inhibitors Product Portfolio Table 104. Mylan Recent Development Table 105. Pfizer Company Information Table 106. Pfizer Business Overview Table 107. Pfizer Oral Factor Xa Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. Pfizer Oral Factor Xa Inhibitors Product Portfolio Table 109. Pfizer Recent Development Table 110. Zydus Company Information Table 111. Zydus Business Overview Table 112. Zydus Oral Factor Xa Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 113. Zydus Oral Factor Xa Inhibitors Product Portfolio Table 114. Zydus Recent Development Table 115. HEC Pharma Company Information Table 116. HEC Pharma Business Overview Table 117. HEC Pharma Oral Factor Xa Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 118. HEC Pharma Oral Factor Xa Inhibitors Product Portfolio Table 119. HEC Pharma Recent Development Table 120. Hansoh Pharma Company Information Table 121. Hansoh Pharma Business Overview Table 122. Hansoh Pharma Oral Factor Xa Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 123. Hansoh Pharma Oral Factor Xa Inhibitors Product Portfolio Table 124. Hansoh Pharma Recent Development Table 125. Huahai Pharmaceutical Company Information Table 126. Huahai Pharmaceutical Business Overview Table 127. Huahai Pharmaceutical Oral Factor Xa Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 128. Huahai Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio Table 129. Huahai Pharmaceutical Recent Development Table 130. Shanghai Huilun Pharmaceutical Company Information Table 131. Shanghai Huilun Pharmaceutical Business Overview Table 132. Shanghai Huilun Pharmaceutical Oral Factor Xa Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 133. Shanghai Huilun Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio Table 134. Shanghai Huilun Pharmaceutical Recent Development Table 135. Qilu Pharmaceutical Company Information Table 136. Qilu Pharmaceutical Business Overview Table 137. Qilu Pharmaceutical Oral Factor Xa Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 138. Qilu Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio Table 139. Qilu Pharmaceutical Recent Development Table 140. Cspc Ouyi Pharmaceutical Company Information Table 141. Cspc Ouyi Pharmaceutical Business Overview Table 142. Cspc Ouyi Pharmaceutical Oral Factor Xa Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 143. Cspc Ouyi Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio Table 144. Cspc Ouyi Pharmaceutical Recent Development Table 145. Yangtze River Pharmaceutical Company Information Table 146. Yangtze River Pharmaceutical Business Overview Table 147. Yangtze River Pharmaceutical Oral Factor Xa Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 148. Yangtze River Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio Table 149. Yangtze River Pharmaceutical Recent Development Table 150. Zhejiang Hisun Pharmaceutical Company Information Table 151. Zhejiang Hisun Pharmaceutical Business Overview Table 152. Zhejiang Hisun Pharmaceutical Oral Factor Xa Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 153. Zhejiang Hisun Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio Table 154. Zhejiang Hisun Pharmaceutical Recent Development Table 155. Chia Tai Tianqing Pharmaceutical Company Information Table 156. Chia Tai Tianqing Pharmaceutical Business Overview Table 157. Chia Tai Tianqing Pharmaceutical Oral Factor Xa Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 158. Chia Tai Tianqing Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio Table 159. Chia Tai Tianqing Pharmaceutical Recent Development Table 160. Key Raw Materials Table 161. Raw Materials Key Suppliers Table 162. Oral Factor Xa Inhibitors Distributors List Table 163. Oral Factor Xa Inhibitors Customers List Table 164. Research Programs/Design for This Report Table 165. Authors List of This Report Table 166. Secondary Sources Table 167. Primary Sources List of Figures Figure 1. Oral Factor Xa Inhibitors Product Image Figure 2. Global Oral Factor Xa Inhibitors Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Oral Factor Xa Inhibitors Market Size (2021-2032) & (US$ Million) Figure 4. Global Oral Factor Xa Inhibitors Sales (2021-2032) & (K Units) Figure 5. Global Oral Factor Xa Inhibitors Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Oral Factor Xa Inhibitors Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Edoxaban Image Figure 9. Rivaroxaban Image Figure 10. Apixaban Image Figure 11. Global Oral Factor Xa Inhibitors Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Oral Factor Xa Inhibitors Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Oral Factor Xa Inhibitors Sales Market Share by Type (2021-2032) Figure 14. Global Oral Factor Xa Inhibitors Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Oral Factor Xa Inhibitors Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Oral Factor Xa Inhibitors Revenue Market Share by Type (2021-2032) Figure 17. Pulmonary Embolism Image Figure 18. Deep Vein Thrombosis Image Figure 19. Atrial Fibrillation Image Figure 20. Other Image Figure 21. Global Oral Factor Xa Inhibitors Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Oral Factor Xa Inhibitors Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global Oral Factor Xa Inhibitors Sales Market Share by Application (2021-2032) Figure 24. Global Oral Factor Xa Inhibitors Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global Oral Factor Xa Inhibitors Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global Oral Factor Xa Inhibitors Revenue Market Share by Application (2021-2032) Figure 27. North America Oral Factor Xa Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 28. North America Oral Factor Xa Inhibitors Sales Market Share by Country (2021-2032) Figure 29. U.S. Oral Factor Xa Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Canada Oral Factor Xa Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Mexico Oral Factor Xa Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe Oral Factor Xa Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Oral Factor Xa Inhibitors Sales Market Share by Country (2021-2032) Figure 34. Germany Oral Factor Xa Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 35. France Oral Factor Xa Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 36. U.K. Oral Factor Xa Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Italy Oral Factor Xa Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Netherlands Oral Factor Xa Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific Oral Factor Xa Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Oral Factor Xa Inhibitors Sales Market Share by Country (2021-2032) Figure 41. China Oral Factor Xa Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Japan Oral Factor Xa Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 43. South Korea Oral Factor Xa Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Southeast Asia Oral Factor Xa Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 45. India Oral Factor Xa Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 46. Australia Oral Factor Xa Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa Oral Factor Xa Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Oral Factor Xa Inhibitors Sales Market Share by Country (2021-2032) Figure 49. Brazil Oral Factor Xa Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South Africa Oral Factor Xa Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Saudi Arabia Oral Factor Xa Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Turkey Oral Factor Xa Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Argentina Oral Factor Xa Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 54. UAE Oral Factor Xa Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Egypt Oral Factor Xa Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Chile Oral Factor Xa Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Global Oral Factor Xa Inhibitors Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global Oral Factor Xa Inhibitors Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America Oral Factor Xa Inhibitors Revenue (2021-2032) & (US$ Million) Figure 60. North America Oral Factor Xa Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe Oral Factor Xa Inhibitors Revenue (2021-2032) & (US$ Million) Figure 62. Europe Oral Factor Xa Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Oral Factor Xa Inhibitors Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific Oral Factor Xa Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa Oral Factor Xa Inhibitors Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa Oral Factor Xa Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Oral Factor Xa Inhibitors Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Oral Factor Xa Inhibitors Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Edoxaban
  • Rivaroxaban
  • Apixaban
Applications
  • Pulmonary Embolism
  • Deep Vein Thrombosis
  • Atrial Fibrillation
  • Other
Companies covered
  • Accord Healthcare
  • Apotex
  • Bayer
  • Bristol Myers Squibb
  • Daiichi Sankyo
  • Janssen Pharmaceuticals
  • Lupin
  • Mylan
  • Pfizer
  • Zydus
  • HEC Pharma
  • Hansoh Pharma
  • Huahai Pharmaceutical
  • Shanghai Huilun Pharmaceutical
  • Qilu Pharmaceutical
  • Cspc Ouyi Pharmaceutical
  • Yangtze River Pharmaceutical
  • Zhejiang Hisun Pharmaceutical
  • Chia Tai Tianqing Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Oral Factor Xa Inhibitors Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Oral Factor Xa Inhibitors Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Oral Factor Xa Inhibitors Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Oral Factor Xa Inhibitors Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Oral Factor Xa Inhibitors Market Dynamics
  1. 2.1 Oral Factor Xa Inhibitors Industry Trends
  2. 2.2 Oral Factor Xa Inhibitors Industry Drivers
  3. 2.3 Oral Factor Xa Inhibitors Industry Opportunities and Challenges
  4. 2.4 Oral Factor Xa Inhibitors Industry Restraints
3 Oral Factor Xa Inhibitors Market by Manufacturers
  1. 3.1 Global Oral Factor Xa Inhibitors Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Oral Factor Xa Inhibitors Sales by Manufacturers (2021-2026)
  3. 3.3 Global Oral Factor Xa Inhibitors Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Oral Factor Xa Inhibitors Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Oral Factor Xa Inhibitors Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Oral Factor Xa Inhibitors Manufacturers, Product Type & Application
  7. 3.7 Global Oral Factor Xa Inhibitors Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Oral Factor Xa Inhibitors Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Oral Factor Xa Inhibitors Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Oral Factor Xa Inhibitors Tier 1, Tier 2, and Tier 3
4 Oral Factor Xa Inhibitors Market by Type
  1. 4.1 Oral Factor Xa Inhibitors Type Introduction
  2. 4.1.1 Edoxaban
  3. 4.1.2 Rivaroxaban
  4. 4.1.3 Apixaban
  5. 4.2 Global Oral Factor Xa Inhibitors Sales by Type
  6. 4.2.1 Global Oral Factor Xa Inhibitors Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Oral Factor Xa Inhibitors Sales by Type (2021-2032)
  8. 4.2.3 Global Oral Factor Xa Inhibitors Sales Market Share by Type (2021-2032)
  9. 4.3 Global Oral Factor Xa Inhibitors Revenue by Type
  10. 4.3.1 Global Oral Factor Xa Inhibitors Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Oral Factor Xa Inhibitors Revenue by Type (2021-2032)
  12. 4.3.3 Global Oral Factor Xa Inhibitors Revenue Market Share by Type (2021-2032)
5 Oral Factor Xa Inhibitors Market by Application
  1. 5.1 Oral Factor Xa Inhibitors Application Introduction
  2. 5.1.1 Pulmonary Embolism
  3. 5.1.2 Deep Vein Thrombosis
  4. 5.1.3 Atrial Fibrillation
  5. 5.1.4 Other
  6. 5.2 Global Oral Factor Xa Inhibitors Sales by Application
  7. 5.2.1 Global Oral Factor Xa Inhibitors Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Oral Factor Xa Inhibitors Sales by Application (2021-2032)
  9. 5.2.3 Global Oral Factor Xa Inhibitors Sales Market Share by Application (2021-2032)
  10. 5.3 Global Oral Factor Xa Inhibitors Revenue by Application
  11. 5.3.1 Global Oral Factor Xa Inhibitors Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Oral Factor Xa Inhibitors Revenue by Application (2021-2032)
  13. 5.3.3 Global Oral Factor Xa Inhibitors Revenue Market Share by Application (2021-2032)
6 Global Oral Factor Xa Inhibitors Sales by Region
  1. 6.1 Global Oral Factor Xa Inhibitors Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Oral Factor Xa Inhibitors Sales by Region (2021-2032)
  3. 6.2.1 Global Oral Factor Xa Inhibitors Sales by Region (2021-2026)
  4. 6.2.2 Global Oral Factor Xa Inhibitors Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Oral Factor Xa Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Oral Factor Xa Inhibitors Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Oral Factor Xa Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Oral Factor Xa Inhibitors Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Oral Factor Xa Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Oral Factor Xa Inhibitors Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Oral Factor Xa Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Oral Factor Xa Inhibitors Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Oral Factor Xa Inhibitors Revenue by Region
  1. 7.1 Global Oral Factor Xa Inhibitors Revenue by Region
  2. 7.1.1 Global Oral Factor Xa Inhibitors Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Oral Factor Xa Inhibitors Revenue by Region (2021-2026)
  4. 7.1.3 Global Oral Factor Xa Inhibitors Revenue by Region (2027-2032)
  5. 7.1.4 Global Oral Factor Xa Inhibitors Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Oral Factor Xa Inhibitors Revenue (2021-2032)
  8. 7.2.2 North America Oral Factor Xa Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Oral Factor Xa Inhibitors Revenue (2021-2032)
  11. 7.3.2 Europe Oral Factor Xa Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Oral Factor Xa Inhibitors Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Oral Factor Xa Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Oral Factor Xa Inhibitors Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Oral Factor Xa Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Accord Healthcare
  2. 8.1.1 Accord Healthcare Company Information
  3. 8.1.2 Accord Healthcare Business Overview
  4. 8.1.3 Accord Healthcare Oral Factor Xa Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Accord Healthcare Oral Factor Xa Inhibitors Product Portfolio
  6. 8.1.5 Accord Healthcare Recent Developments
  7. 8.2 Apotex
  8. 8.2.1 Apotex Company Information
  9. 8.2.2 Apotex Business Overview
  10. 8.2.3 Apotex Oral Factor Xa Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Apotex Oral Factor Xa Inhibitors Product Portfolio
  12. 8.2.5 Apotex Recent Developments
  13. 8.3 Bayer
  14. 8.3.1 Bayer Company Information
  15. 8.3.2 Bayer Business Overview
  16. 8.3.3 Bayer Oral Factor Xa Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Bayer Oral Factor Xa Inhibitors Product Portfolio
  18. 8.3.5 Bayer Recent Developments
  19. 8.4 Bristol Myers Squibb
  20. 8.4.1 Bristol Myers Squibb Company Information
  21. 8.4.2 Bristol Myers Squibb Business Overview
  22. 8.4.3 Bristol Myers Squibb Oral Factor Xa Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Bristol Myers Squibb Oral Factor Xa Inhibitors Product Portfolio
  24. 8.4.5 Bristol Myers Squibb Recent Developments
  25. 8.5 Daiichi Sankyo
  26. 8.5.1 Daiichi Sankyo Company Information
  27. 8.5.2 Daiichi Sankyo Business Overview
  28. 8.5.3 Daiichi Sankyo Oral Factor Xa Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Daiichi Sankyo Oral Factor Xa Inhibitors Product Portfolio
  30. 8.5.5 Daiichi Sankyo Recent Developments
  31. 8.6 Janssen Pharmaceuticals
  32. 8.6.1 Janssen Pharmaceuticals Company Information
  33. 8.6.2 Janssen Pharmaceuticals Business Overview
  34. 8.6.3 Janssen Pharmaceuticals Oral Factor Xa Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Janssen Pharmaceuticals Oral Factor Xa Inhibitors Product Portfolio
  36. 8.6.5 Janssen Pharmaceuticals Recent Developments
  37. 8.7 Lupin
  38. 8.7.1 Lupin Company Information
  39. 8.7.2 Lupin Business Overview
  40. 8.7.3 Lupin Oral Factor Xa Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Lupin Oral Factor Xa Inhibitors Product Portfolio
  42. 8.7.5 Lupin Recent Developments
  43. 8.8 Mylan
  44. 8.8.1 Mylan Company Information
  45. 8.8.2 Mylan Business Overview
  46. 8.8.3 Mylan Oral Factor Xa Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Mylan Oral Factor Xa Inhibitors Product Portfolio
  48. 8.8.5 Mylan Recent Developments
  49. 8.9 Pfizer
  50. 8.9.1 Pfizer Company Information
  51. 8.9.2 Pfizer Business Overview
  52. 8.9.3 Pfizer Oral Factor Xa Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Pfizer Oral Factor Xa Inhibitors Product Portfolio
  54. 8.9.5 Pfizer Recent Developments
  55. 8.10 Zydus
  56. 8.10.1 Zydus Company Information
  57. 8.10.2 Zydus Business Overview
  58. 8.10.3 Zydus Oral Factor Xa Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Zydus Oral Factor Xa Inhibitors Product Portfolio
  60. 8.10.5 Zydus Recent Developments
  61. 8.11 HEC Pharma
  62. 8.11.1 HEC Pharma Company Information
  63. 8.11.2 HEC Pharma Business Overview
  64. 8.11.3 HEC Pharma Oral Factor Xa Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 HEC Pharma Oral Factor Xa Inhibitors Product Portfolio
  66. 8.11.5 HEC Pharma Recent Developments
  67. 8.12 Hansoh Pharma
  68. 8.12.1 Hansoh Pharma Company Information
  69. 8.12.2 Hansoh Pharma Business Overview
  70. 8.12.3 Hansoh Pharma Oral Factor Xa Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Hansoh Pharma Oral Factor Xa Inhibitors Product Portfolio
  72. 8.12.5 Hansoh Pharma Recent Developments
  73. 8.13 Huahai Pharmaceutical
  74. 8.13.1 Huahai Pharmaceutical Company Information
  75. 8.13.2 Huahai Pharmaceutical Business Overview
  76. 8.13.3 Huahai Pharmaceutical Oral Factor Xa Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Huahai Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio
  78. 8.13.5 Huahai Pharmaceutical Recent Developments
  79. 8.14 Shanghai Huilun Pharmaceutical
  80. 8.14.1 Shanghai Huilun Pharmaceutical Company Information
  81. 8.14.2 Shanghai Huilun Pharmaceutical Business Overview
  82. 8.14.3 Shanghai Huilun Pharmaceutical Oral Factor Xa Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Shanghai Huilun Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio
  84. 8.14.5 Shanghai Huilun Pharmaceutical Recent Developments
  85. 8.15 Qilu Pharmaceutical
  86. 8.15.1 Qilu Pharmaceutical Company Information
  87. 8.15.2 Qilu Pharmaceutical Business Overview
  88. 8.15.3 Qilu Pharmaceutical Oral Factor Xa Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Qilu Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio
  90. 8.15.5 Qilu Pharmaceutical Recent Developments
  91. 8.16 Cspc Ouyi Pharmaceutical
  92. 8.16.1 Cspc Ouyi Pharmaceutical Company Information
  93. 8.16.2 Cspc Ouyi Pharmaceutical Business Overview
  94. 8.16.3 Cspc Ouyi Pharmaceutical Oral Factor Xa Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Cspc Ouyi Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio
  96. 8.16.5 Cspc Ouyi Pharmaceutical Recent Developments
  97. 8.17 Yangtze River Pharmaceutical
  98. 8.17.1 Yangtze River Pharmaceutical Company Information
  99. 8.17.2 Yangtze River Pharmaceutical Business Overview
  100. 8.17.3 Yangtze River Pharmaceutical Oral Factor Xa Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Yangtze River Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio
  102. 8.17.5 Yangtze River Pharmaceutical Recent Developments
  103. 8.18 Zhejiang Hisun Pharmaceutical
  104. 8.18.1 Zhejiang Hisun Pharmaceutical Company Information
  105. 8.18.2 Zhejiang Hisun Pharmaceutical Business Overview
  106. 8.18.3 Zhejiang Hisun Pharmaceutical Oral Factor Xa Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Zhejiang Hisun Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio
  108. 8.18.5 Zhejiang Hisun Pharmaceutical Recent Developments
  109. 8.19 Chia Tai Tianqing Pharmaceutical
  110. 8.19.1 Chia Tai Tianqing Pharmaceutical Company Information
  111. 8.19.2 Chia Tai Tianqing Pharmaceutical Business Overview
  112. 8.19.3 Chia Tai Tianqing Pharmaceutical Oral Factor Xa Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Chia Tai Tianqing Pharmaceutical Oral Factor Xa Inhibitors Product Portfolio
  114. 8.19.5 Chia Tai Tianqing Pharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Oral Factor Xa Inhibitors Value Chain Analysis
  2. 9.1.1 Oral Factor Xa Inhibitors Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Oral Factor Xa Inhibitors Production Mode & Process
  6. 9.2 Oral Factor Xa Inhibitors Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Oral Factor Xa Inhibitors Distributors
  9. 9.2.3 Oral Factor Xa Inhibitors Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst